About this trial
The goal of this clinical trial is to evaluate whether a combined intervention of therapeutic exercise and anti-inflammatory nutritional supplementation improves physical performance and reduces systemic inflammation in frail, malnourished older adults. The main questions it aims to answer are:
Does the addition of an anti-inflammatory nutritional supplement (Alisenoc™) to a multicomponent exercise program (Vivifrail) lead to greater improvements in physical performance compared to standard exercise and conventional nutritional support?
Does the combined intervention reduce levels of inflammatory biomarkers (e.g., IL-6, TNF-α, IL-8, GDF-15) in this population?
Are there measurable changes in body composition (e.g., muscle mass, fat mass, bone health) following the intervention?
Does the intervention impact clinical outcomes such as hospital readmissions, functional independence, or mortality over the following 12 months?
Researchers will compare two groups:
One group receiving the Vivifrail exercise program plus a daily dose of the anti-inflammatory nutritional supplement Alisenoc™.
Another group receiving the same Vivifrail program plus an isocaloric, protein-equivalent conventional supplement.
Participants will:
Be aged 75 years or older and identified as frail and malnourished according to Fried and GLIM criteria.
Undergo baseline evaluation including functional performance (SPPB), body composition via bioimpedance analysis, and blood sample collection for inflammatory biomarkers.
Be randomly assigned to one of the two intervention groups.
Follow a 12-week home-based multicomponent exercise program guided by educational materials and supervised remotely.
Consume the assigned oral nutritional supplement daily for the same 12-week period.
Return for outcome assessments at 12 weeks, and again at 6 and 12 months for long-term follow-up.
All study procedures will take place at the Hospital Universitario de Navarra (HUN), Spain. Participants will be recruited from outpatient geriatrics and nutrition clinics and assessed at a dedicated research unit with nursing support. The intervention is designed to be feasible, scalable, and representative of real-world multidisciplinary care in older populations with high vulnerability.
The study aims to provide evidence for an integrative, personalized approach to reversing frailty through combined physical and nutritional strategies targeting the biological basis of inflammaging.
Eligibility criteria
Qualifiers
Patient aged ≥ 75 years.
Diagnosis of frailty according to Linda Fried's criteria.
Diagnosis of malnutrition according to GLIM (Global Leadership Initiative on Malnutrition) criteria.
Barthel Index score ≥ 60 points.
Disqualifiers
Presence of type 1 or type 2 diabetes mellitus with poor metabolic control (HbA1c > 8% or insulin-dependent).
Oropharyngeal dysphagia to liquids that prevents safe intake of oral supplementation.
Moderate-to-severe cognitive impairment, defined as a score ≥ 5 on the Global Deterioration Scale (GDS) of Reisberg.
Refusal to sign the informed consent by the patient, primary caregiver, or legal representative, or inability to obtain it.
Trial design
Treatments tested in this trial
- Anti-Inflammatory Supplement
- Conventional Nutritional Supplement
Treatment groups
Locations
Sponsors and collaborators
Fundacion Miguel Servet
Lead sponsor
Adventia Pharma
Collaborator